FATE THERAPEUTICS INC (FATE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
FATE currently has 120M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 5.78% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 120.0M shares outstanding |
120M | 0 |
| Aug 12, 2025 |
10-Q filing | 118.5M shares outstanding |
120M | 0 |
| May 13, 2025 |
10-Q filing | 118.4M shares outstanding |
120M | 0 |
| Mar 05, 2025 |
10-K filing | 113.7M shares outstanding |
110M | 0 |
| Nov 12, 2024 |
10-Q filing | 117.8M shares outstanding |
120M | 0 |
| Aug 13, 2024 |
10-Q filing | 117.5M shares outstanding |
120M | 0 |
| May 09, 2024 |
10-Q filing | 113.8M shares outstanding |
110M | 0 |
| Apr 18, 2024 |
S-3 filing: Resale of common stock issuable upon exercise of pre-funded warrants by the selling stockholder. |
98M | 3.6M |
| Feb 26, 2024 |
10-K filing | 98.4M shares outstanding |
98M | 0 |
| Nov 08, 2023 |
10-Q filing | 98.6M shares outstanding |
99M | 0 |
| Nov 08, 2023 |
S-3 filing: Fate Therapeutics, Inc. is filing an S-3 to register the offering of up to $300,000,000 of its common stock, preferred stock, and/or debt securities. |
98M | 0 |
| Aug 08, 2023 |
10-Q filing | 98.4M shares outstanding |
98M | 0 |
| May 03, 2023 |
10-Q filing | 98.1M shares outstanding |
98M | 0 |
| Feb 28, 2023 |
10-K filing | 96.8M shares outstanding |
97M | 0 |
| Nov 03, 2022 |
10-Q filing | 97.0M shares outstanding |
97M | 0 |
| Aug 03, 2022 |
10-Q filing | 96.7M shares outstanding |
97M | 0 |
| May 04, 2022 |
10-Q filing | 96.6M shares outstanding |
97M | 0 |
| Feb 28, 2022 |
10-K filing | 96.4M shares outstanding |
96M | 0 |
| Nov 04, 2021 |
10-Q filing | 95.5M shares outstanding |
95M | 0 |
| Aug 04, 2021 |
10-Q filing | 95.2M shares outstanding |
95M | 0 |
| May 05, 2021 |
10-Q filing | 94.0M shares outstanding |
94M | 0 |
| Feb 24, 2021 |
10-K filing | 93.8M shares outstanding |
94M | 0 |
| Nov 05, 2020 |
10-Q filing | 87.2M shares outstanding |
87M | 0 |
| Aug 05, 2020 |
10-Q filing | 86.8M shares outstanding |
87M | 0 |
| May 11, 2020 |
10-Q filing | 77.7M shares outstanding |
78M | 0 |
| Apr 02, 2020 |
8-K filing: Fate Therapeutics, Inc. entered into a Collaboration and Option Agreement with Janssen Biotech, Inc. and a Stock Purchase Agreement with Johnson & Johnson Innovation-JJDC, Inc., selling 1,612,904 shares of common stock to JJDC at $31.00 per share for approximately $50 million. ($50.0M proceeds) |
76M | 0 |
| Mar 02, 2020 |
10-K filing | 75.9M shares outstanding |
76M | 0 |